DexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer Sells 45,607 Shares

DexCom, Inc. (NASDAQ:DXCMGet Rating) CEO Kevin R. Sayer sold 45,607 shares of the stock in a transaction on Friday, January 20th. The shares were sold at an average price of $105.75, for a total value of $4,822,940.25. Following the sale, the chief executive officer now owns 426,645 shares of the company’s stock, valued at approximately $45,117,708.75. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

DexCom Stock Performance

NASDAQ DXCM opened at $106.03 on Wednesday. The stock has a 50-day simple moving average of $112.85 and a two-hundred day simple moving average of $99.36. The firm has a market capitalization of $40.95 billion, a P/E ratio of 195.45, a PEG ratio of 2.95 and a beta of 1.14. DexCom, Inc. has a fifty-two week low of $66.89 and a fifty-two week high of $134.76. The company has a debt-to-equity ratio of 1.08, a quick ratio of 3.43 and a current ratio of 3.77.

DexCom (NASDAQ:DXCMGet Rating) last released its quarterly earnings data on Thursday, October 27th. The medical device company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.04. The business had revenue of $769.60 million during the quarter, compared to analyst estimates of $752.67 million. DexCom had a return on equity of 13.27% and a net margin of 8.24%. On average, equities analysts forecast that DexCom, Inc. will post 0.79 earnings per share for the current year.

Institutional Investors Weigh In On DexCom

A number of institutional investors have recently modified their holdings of DXCM. Mirae Asset Global Investments Co. Ltd. grew its position in shares of DexCom by 31.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 270,999 shares of the medical device company’s stock valued at $138,643,000 after acquiring an additional 65,516 shares during the period. Healthcare of Ontario Pension Plan Trust Fund grew its position in shares of DexCom by 3,596.7% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,109 shares of the medical device company’s stock valued at $567,000 after acquiring an additional 1,079 shares during the period. West Family Investments Inc. acquired a new stake in shares of DexCom during the 1st quarter valued at about $209,000. Ergoteles LLC grew its position in shares of DexCom by 60.6% during the 1st quarter. Ergoteles LLC now owns 1,681 shares of the medical device company’s stock valued at $860,000 after acquiring an additional 634 shares during the period. Finally, Mackenzie Financial Corp grew its position in shares of DexCom by 26.4% during the 1st quarter. Mackenzie Financial Corp now owns 29,516 shares of the medical device company’s stock valued at $15,100,000 after acquiring an additional 6,160 shares during the period. 94.01% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently commented on DXCM shares. Morgan Stanley increased their price objective on DexCom from $117.00 to $131.00 and gave the company an “equal weight” rating in a report on Friday, January 6th. Jefferies Financial Group assumed coverage on DexCom in a report on Wednesday, October 12th. They set a “buy” rating and a $125.00 price objective for the company. Cowen raised their target price on DexCom from $85.00 to $114.00 in a research note on Friday, October 28th. BTIG Research raised their target price on DexCom to $126.00 in a research note on Tuesday, November 1st. Finally, Raymond James raised their target price on DexCom from $101.00 to $125.00 and gave the stock an “outperform” rating in a research note on Friday, October 28th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, DexCom has a consensus rating of “Moderate Buy” and an average target price of $122.00.

DexCom Company Profile

(Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

Recommended Stories

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.